Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Trial Profile

Long Term Immunogenicity up to 15 Years After the First Booster Immunization With GSK Biologicals' Encepur Adults (Polygeline-free Tick-Borne Encephalitis Vaccine for Adults) in Adults Who Received 1 of 3 Different Primary Vaccination Schedules

Status: Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 07 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tick-borne encephalitis vaccine (Primary)
  • Indications Encephalitis
  • Focus Pharmacodynamics
  • Acronyms TBEV POLYGELINE FREE-025 EXT:021
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 28 Jun 2018 Planned End Date changed from 3 Nov 2021 to 14 Jul 2022.
    • 28 Jun 2018 Planned primary completion date changed from 3 Nov 2021 to 14 Jul 2022.
    • 15 Jan 2018 Planned End Date changed from 7 Apr 2022 to 3 Nov 2021.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top